Evidence map›Paper›PMID 21757659›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2011

Nuclear factor of activated T cells 5 regulates vascular smooth muscle cell phenotypic modulation.

Julia A Halterman, H Moo Kwon, Ramin Zargham, Pamela D Schoppee Bortz, Brian R Wamhoff

Open access · greenAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. High NaBiomedicines · 2021
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Understanding the Two Faces of Low-Salt Intake.Current hypertension reports · 2017
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Julia A HaltermanDepartment of Pharmacology, Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, USA.
H Moo Kwon
Ramin Zargham
Pamela D Schoppee Bortz
Brian R Wamhoff
University of Maryland, Baltimore · US

Funding

Tonicity signaling to TonEBP transcription factorR01DK061677 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI KWON, H MOO · 2002 to 2012
$3.2M
Calcium-dependent Regulation of Smooth Muscle PhenotypeR01HL081682 · NHLBI · UNIVERSITY OF VIRGINIA · PI WAMHOFF, BRIAN ROBERT · 2006 to 2010
$1.5M
NHLBI NIH HHS HL81682NHLBI NIH HHS R01 HL081682NIDDK NIH HHS R01 DK061677NIDDK NIH HHS R01-DK61677
6 · The paper itself

Abstract

objectiveThe tonicity-responsive transcription factor, nuclear factor of activated T cells 5 (NFAT5/tonicity enhancer binding protein [TonEBP]), has been well characterized in numerous cell types; however, NFAT5 function in vascular smooth muscle cells (SMCs) is unknown. Our main objective was to determine the role of NFAT5 regulation in SMCs. METHODS AND

resultsWe showed that NFAT5 is regulated by hypertonicity in SMCs and is upregulated in atherosclerosis and neointimal hyperplasia. RNAi knockdown of NFAT5 inhibited basal expression of several SMC differentiation marker genes, including smooth muscle α actin (SMαA). Bioinformatic analysis of SMαA revealed 7 putative NFAT5 binding sites in the first intron, and chromatin immunoprecipitation analysis showed NFAT5 enrichment of intronic DNA. Overexpression of NFAT5 increased SMαA promoter-intron activity, which requires an NFAT5 cis element at +1012, whereas dominant-negative NFAT5 decreased SMαA promoter-intron activity. Because it is unlikely that SMCs experience extreme changes in tonicity, we investigated other stimuli and uncovered 2 novel NFAT5-inducing factors: angiotensin II, a contractile agonist, and platelet-derived growth factor-BB (PDGF-BB), a potent mitogen in vascular injury. Angiotensin II stimulated NFAT5 translocation and activity, and NFAT5 knockdown inhibited an angiotensin II-mediated upregulation of SMαA mRNA. PDGF-BB increased NFAT5 protein, and loss of NFAT5 inhibited PDGF-BB-induced SMC migration.

conclusionsWe have identified NFAT5 as a novel regulator of SMC phenotypic modulation and have uncovered the role of NFAT5 in angiotensin II-induced SMαA expression and PDGF-BB-stimulated SMC migration.

Indexed as

ActinsAngiotensin IIAnimalsApolipoproteins EAtherosclerosisBecaplerminBinding SitesCarotid Artery InjuriesCell MovementCell ProliferationCells, CulturedChromatin ImmunoprecipitationCoculture TechniquesComputational BiologyDisease Models, AnimalGene Expression RegulationActa2 protein, ratActinsAngiotensin IIApolipoproteins EBecaplerminNFAT5 protein, humanNfat5 protein, mouseNfat5 protein, ratNFATC Transcription FactorsPlatelet-Derived Growth FactorProto-Oncogene Proteins c-sisRNA, MessengerTranscription Factors

Identifiers

PMID21757659
PMCPMC3188807
OpenAlexW2167413184

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.